Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study - supplementary table

<b>Aim: </b>Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. <b>Patients &amp; methods: </b>Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg<b>/</b>10 ml 5- h subcutaneous infusion for <b>≤</b>7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <b>&lt;</b>72 h. <b>Results: </b>Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. Sixty-six control patients identified and were wellmatched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of $16,995 (p <b>&lt; </b>0.001). <b>Conclusion: </b>Furoscix use was associated with significant reductions in 30-day HF-related healthcare costs versus matched hospitalized controls.